Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Fenfluramine for the Treatment of Refractory Epilepsy in Adult Dravet Patients

NCT05560282 is registered in ClinicalTrials.gov with University Health Network, Toronto as lead sponsor.

NCT NCT05560282
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05560282 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Fenfluramine for the Treatment of Refractory Epilepsy in Adult Dravet Patients
Lead sponsor
University Health Network, Toronto
Phase
Phase 3
Overall status
Terminated
Start date
January 11, 2023
Completion date
May 13, 2025
Enrollment
7 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

dravet syndrome, dravet syndrome, intractable